Latest Content

A phase 2 study of dose-adjusted EPOCH plus tafasitamab with or without rituximab met its primary end point of MRD negativity after the first cycle.

Fixed-duration venetoclax/obinutuzumab more than doubled median PFS vs chlorambucil/obinutuzumab in previously untreated CLL.

In the MAXILUS primary analysis, luspatercept initiated at 1.75 mg/kg yielded high RBC transfusion independence rates in lower-risk MDS.

The FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation–naive or sensitive prostate cancer.

Revumenib yielded responses across subgroups with relapsed/refractory, NPM1-mutated AML and co-mutations, as well as in KMT2A-rearranged acute leukemia.

The FDA has approved adjuvant belzutifan plus pembrolizumab for patients with ccRCC at intermediate-high or high risk of recurrence.

Lurbinectedin alone or with irinotecan did not improve OS vs topotecan or irinotecan alone in patients with relapsed SCLC.

A 10-week resistance program boosted cancer survivors’ strength, immune function, and gut microbiome.

Partial response to bridging therapy before cilta-cel was associated with improved PFS and OS outcomes in relapsed/refractory multiple myeloma.

Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.

Ficerafusp alfa plus pembrolizumab generated a 54% ORR and 21.7-month median DOR in first-line HPV-negative recurrent or metastatic HNSCC.

EPCORE FL-1 showed that epcoritamab/lenalidomide/rituximab yielded superior efficacy vs lenalidomide/rituximab across follicular lymphoma populations.

Azacitidine plus venetoclax and ivosidenib produced robust responses and induced high rates of MRD negativity in IDH1-mutated newly diagnosed AML.